Halozyme Therapeutics (HALO) Competitors $65.13 +1.09 (+1.70%) Closing price 08/13/2025 04:00 PM EasternExtended Trading$64.78 -0.34 (-0.53%) As of 08/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HALO vs. BIIB, INCY, UTHR, NBIX, BMRN, EXEL, EXAS, IONS, MDGL, and RGENShould you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Exact Sciences (EXAS), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Halozyme Therapeutics vs. Its Competitors Biogen Incyte United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Exact Sciences Ionis Pharmaceuticals Madrigal Pharmaceuticals Repligen Biogen (NASDAQ:BIIB) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings. Which has more volatility & risk, BIIB or HALO? Biogen has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Do analysts recommend BIIB or HALO? Biogen presently has a consensus price target of $185.63, suggesting a potential upside of 37.29%. Halozyme Therapeutics has a consensus price target of $66.56, suggesting a potential upside of 2.19%. Given Biogen's stronger consensus rating and higher probable upside, analysts plainly believe Biogen is more favorable than Halozyme Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34Halozyme Therapeutics 2 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.18 Which has better valuation and earnings, BIIB or HALO? Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.05$1.63B$10.4612.93Halozyme Therapeutics$1.02B7.90$444.09M$4.3714.90 Does the media favor BIIB or HALO? In the previous week, Biogen had 20 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 39 mentions for Biogen and 19 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.06 beat Biogen's score of 0.88 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 23 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BIIB or HALO more profitable? Halozyme Therapeutics has a net margin of 47.28% compared to Biogen's net margin of 15.31%. Halozyme Therapeutics' return on equity of 150.85% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Halozyme Therapeutics 47.28%150.85%29.19% Do insiders and institutionals have more ownership in BIIB or HALO? 87.9% of Biogen shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryHalozyme Therapeutics beats Biogen on 9 of the 16 factors compared between the two stocks. Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HALO vs. The Competition Export to ExcelMetricHalozyme TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.89B$3.04B$5.55B$9.83BDividend YieldN/A2.27%4.62%4.12%P/E Ratio14.9020.6730.1526.03Price / Sales7.90365.71462.17105.47Price / Cash13.7742.0537.7558.93Price / Book24.127.638.476.06Net Income$444.09M-$54.65M$3.26B$265.11M7 Day Performance4.88%5.41%4.17%3.38%1 Month Performance12.97%7.14%4.63%2.28%1 Year Performance13.45%31.27%34.95%29.67% Halozyme Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HALOHalozyme Therapeutics4.8887 of 5 stars$65.13+1.7%$66.56+2.2%+16.3%$7.89B$1.02B14.90390Positive NewsInsider TradeBIIBBiogen4.9569 of 5 stars$132.20+0.2%$185.63+40.4%-33.7%$19.35B$9.68B12.647,605Trending NewsAnalyst RevisionINCYIncyte4.7488 of 5 stars$78.04+3.2%$79.73+2.2%+38.4%$14.76B$4.24B17.742,617UTHRUnited Therapeutics4.8669 of 5 stars$292.65-0.6%$379.69+29.7%-4.3%$13.27B$2.88B11.421,305Positive NewsAnalyst ForecastNBIXNeurocrine Biosciences4.9099 of 5 stars$128.04-0.7%$160.90+25.7%-12.7%$12.79B$2.36B37.881,800Positive NewsInsider TradeBMRNBioMarin Pharmaceutical4.9963 of 5 stars$60.31+3.7%$93.74+55.4%-35.9%$11.15B$2.85B22.423,040News CoveragePositive NewsHigh Trading VolumeEXELExelixis4.9451 of 5 stars$36.81-1.2%$44.44+20.7%+44.2%$10.03B$2.17B17.701,147Positive NewsAnalyst ForecastEXASExact Sciences4.7223 of 5 stars$46.83-1.9%$70.50+50.5%-23.6%$9.01B$2.76B-8.507,000Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionIONSIonis Pharmaceuticals4.5574 of 5 stars$43.45+1.0%$59.38+36.7%-8.1%$6.86B$705M-23.611,069Analyst ForecastMDGLMadrigal Pharmaceuticals3.8671 of 5 stars$312.11+3.3%$420.63+34.8%+53.3%$6.71B$180.13M-17.2990Trending NewsAnalyst ForecastInsider TradeRGENRepligen4.9355 of 5 stars$116.50-2.0%$169.45+45.5%-22.7%$6.68B$634.44M-465.981,778Positive NewsInsider Trade Related Companies and Tools Related Companies BIIB Competitors INCY Competitors UTHR Competitors NBIX Competitors BMRN Competitors EXEL Competitors EXAS Competitors IONS Competitors MDGL Competitors RGEN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HALO) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredD.C.’s secret plan to crush the debt.At a recent gathering with some of the most powerful people in America, Jeff discovered the Trump administrati...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access